tyrosine has been researched along with alpha-aminopyridine in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blanchard, SG; Brackeen, MF; Brown, KK; Cobb, JE; Collins, JL; Harrington, WW; Hashim, MA; Henke, BR; Hull-Ryde, EA; Kaldor, I; Kliewer, SA; Lake, DH; Leesnitzer, LM; Lehmann, JM; Lenhard, JM; Miller, JF; Mook, RA; Noble, SA; Oliver, W; Orband-Miller, LA; Parks, DJ; Plunket, KD; Szewczyk, JR; Willson, TM | 1 |
| Cucinotta, V; Giuffrida, A; Maccarrone, G; Messina, M; Vecchio, G | 1 |
| Downing, JR | 1 |
| Berchuck, JE; Carr, SA; Carroll, M; Clauser, K; Davis, TN; DeAngelo, DJ; Galinsky, I; Golub, TR; Hahn, CK; Hahn, WC; Kakoza, RM; Kung, AL; Root, DE; Ross, KN; Ross, L; Schinzel, AC; Silver, SJ; Stegmaier, K; Stone, RM | 1 |
| Koenig, M; Kwok, C; Liang, C; Lim, ST; McMahon, G; Mielgo, A; Nam, JO; Patel, N; Schlaepfer, DD; Stupack, DG; Sun, C; Tanjoni, I; Tomar, A; Uryu, S; Walsh, C | 1 |
| Kwok, C; Luo, H; McMahon, G; Nam, JO; Patel, N; Phillips, A; Schlaepfer, DD; Stupack, DG; Tanjoni, I; Tomar, A; Uryu, S; Walsh, C | 1 |
| Appleton, BA; Blank, J; Buck, E; Degenkolbe, E; Drueckes, P; Furet, P; Haasen, D; Hofmann, F; Jones, MD; McCarthy, C; Monahan, JE; Ruddy, DA; Schoepfer, J; Sellers, WR; Tiedt, R; Wagner, S; Wartmann, M | 1 |
| Ågren, H; Cheng, J; Sun, X; Tang, Y; Tu, Y; Wang, X | 1 |
8 other study(ies) available for tyrosine and alpha-aminopyridine
| Article | Year |
|---|---|
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
Topics: Administration, Oral; Aminopyridines; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; DNA-Binding Proteins; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Ligands; Lipids; Male; Mice; Oxazoles; Propionates; Radioligand Assay; Rats; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Stereoisomerism; Structure-Activity Relationship; Transcription Factors; Transfection; Tyrosine | 1998 |
Ligand exchange capillary electrophoresis by cyclodextrin derivatives, a powerful tool for enantiomeric separations.
Topics: Amino Acids; Aminopyridines; beta-Cyclodextrins; Cyclodextrins; Electrophoresis, Capillary; Ligands; Phenylalanine; Stereoisomerism; Tryptophan; Tyrosine | 2006 |
Can treating the SYK cell cure leukemia?
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; Gefitinib; Gene Expression Regulation, Leukemic; Genomics; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Morpholines; Oxazines; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyridines; Pyrimidines; Quinazolines; Syk Kinase; Time Factors; Tyrosine | 2009 |
Proteomic and genetic approaches identify Syk as an AML target.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Genomics; HL-60 Cells; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Morpholines; Oxazines; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyridines; Pyrimidines; Quinazolines; RNA Interference; Syk Kinase; Tandem Mass Spectrometry; Time Factors; Tumor Cells, Cultured; Tyrosine; U937 Cells; Xenograft Model Antitumor Assays | 2009 |
PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Crk-Associated Substrate Protein; Female; Focal Adhesion Protein-Tyrosine Kinases; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Phosphorylation; Signal Transduction; Spheroids, Cellular; src-Family Kinases; Tumor Cells, Cultured; Tyrosine; Xenograft Model Antitumor Assays | 2010 |
Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models.
Topics: Administration, Oral; Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Crk-Associated Substrate Protein; Female; Focal Adhesion Protein-Tyrosine Kinases; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Phosphorylation; Tyrosine; Xenograft Model Antitumor Assays | 2010 |
A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.
Topics: Amino Acid Substitution; Aminopyridines; Animals; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Transformed; Cell Line, Tumor; Crystallography, X-Ray; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Mice; Models, Molecular; Mutagenesis; Mutation, Missense; Neoplasms; Point Mutation; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-met; Pyrazoles; Quinolines; Receptors, Growth Factor; Tyrosine | 2011 |
Residues remote from the binding pocket control the antagonist selectivity towards the corticotropin-releasing factor receptor-1.
Topics: Aminopyridines; Binding Sites; Humans; Hydrogen Bonding; Molecular Dynamics Simulation; Protein Structure, Tertiary; Receptors, Corticotropin-Releasing Hormone; Tyrosine | 2015 |